NuCana plc
NCNAHealthcare|Biotechnology|GB
$0.94
+0.00 (+0.40%)
DCF Value
$14.72
Tangible Book / Share
$4.29
Cash / Share
$4.63
Ownership Breakdown
94.1%
Float
6.1M
Shares Outstanding
5.7M
Float Shares
Major Holders (19)
Combined: 76.8%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Hugh S. Griffith | Individual | 12.00% | 2,829,961,890 | Mar 18, 2026 | 13D/G |
| Anta Gkelou | Individual | 5.10% | 4,987,975 | Feb 14, 2025 | 13D/G |
| Karl Naegler | Individual | 5.10% | 4,987,975 | Feb 14, 2025 | 13D/G |
| Henrijette Richter | Individual | 5.10% | 4,987,975 | Feb 14, 2025 | 13D/G |
| Antoine Papiernik | Individual | 5.10% | 4,987,975 | Feb 14, 2025 | 13D/G |
| Graziano Seghezzi | Individual | 5.10% | 4,987,975 | Feb 14, 2025 | 13D/G |
| Sofinnova Partners SAS | Other | 5.10% | 4,987,975 | Feb 14, 2025 | 13D/G |
| Maina Bhaman | Individual | 5.10% | 4,987,975 | Feb 14, 2025 | 13D/G |
| Sofinnova Capital VI FCPR | Other | 5.10% | 4,987,975 | Feb 14, 2025 | 13D/G |
| The Carlyle Group Inc. | Corporation | 2.40% | 3,430,062 | Apr 18, 2025 | 13D/G |
| Abingworth LLP | Partnership | 2.40% | 3,430,062 | Apr 18, 2025 | 13D/G |
| Carlyle Genesis UK LLC | Other | 2.40% | 3,430,062 | Apr 18, 2025 | 13D/G |
| Carlyle Investment Management L.L.C. | Other | 2.40% | 3,430,062 | Apr 18, 2025 | 13D/G |
| TC Group, L.L.C. | Other | 2.40% | 3,430,062 | Apr 18, 2025 | 13D/G |
| CG Subsidiary Holdings L.L.C. | Other | 2.40% | 3,430,062 | Apr 18, 2025 | 13D/G |
| Carlyle Holdings I L.P. | Partnership | 2.40% | 3,430,062 | Apr 18, 2025 | 13D/G |
| Carlyle Holdings I GP Sub L.L.C. | Other | 2.40% | 3,430,062 | Apr 18, 2025 | 13D/G |
| Carlyle Holdings I GP Inc. | Corporation | 2.40% | 3,430,062 | Apr 18, 2025 | 13D/G |
| Abingworth Bioventures VII LP | Partnership | 2.40% | 3,430,062 | Apr 18, 2025 | 13D/G |
Insider Trades (19)
Last 4 quarters: 132,600,130 acquired · 0 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Levy Elliott M. | director | Jun 19, 2026 | DISPOSED | 23,811,896 | — | — | Form 4 |
| Bloss Jeffrey D. | Chief Medical Officer | Jun 19, 2026 | DISPOSED | 36,539,720 | — | — | Form 4 |
| Bruce Theresa Margaret Ms | Chief Operating Officer | Apr 15, 2026 | AWARD | 132,600,130 | — | — | Form 4 |
| Levy Elliott M. | director | Mar 18, 2026 | OTHER | 0 | — | — | Form 4 |
| Levy Elliott M. | director | Mar 18, 2026 | OTHER | 3 | — | — | Form 4 |
| Levy Elliott M. | director | Mar 18, 2026 | OTHER | 28,631,517 | — | — | Form 4 |
| Harrison David James | Head of Translational Medicine | Mar 18, 2026 | OTHER | 77,520,679 | — | — | Form 4 |
| Mellish Martin C.B. | director | Mar 18, 2026 | OTHER | 0 | — | — | Form 4 |
| Mellish Martin C.B. | director | Mar 18, 2026 | OTHER | 7 | — | — | Form 4 |
| Mellish Martin C.B. | director | Mar 18, 2026 | OTHER | 42,362,799 | — | — | Form 4 |
| Bloss Jeffrey D. | Chief Medical Officer | Mar 18, 2026 | OTHER | 0 | — | — | Form 4 |
| Bloss Jeffrey D. | Chief Medical Officer | Mar 18, 2026 | OTHER | 175,742,012 | — | — | Form 4 |
| Webster Ian Alexander | See Remarks | Mar 18, 2026 | OTHER | 54,352,798 | — | — | Form 4 |
| Kay Andrew Martin | director | Mar 18, 2026 | OTHER | 63,648,062 | — | — | Form 4 |
| Leperlier Cyrille | director | Mar 18, 2026 | OTHER | 39,466,743 | — | — | Form 4 |
| Bruce Theresa Margaret Ms | Chief Operating Officer | Mar 18, 2026 | OTHER | 55,139,594 | — | — | Form 4 |
| Griffith Hugh | director, officer: Chief Executive Officer | Mar 18, 2026 | OTHER | 0 | — | — | Form 4 |
| Griffith Hugh | director, officer: Chief Executive Officer | Mar 18, 2026 | OTHER | 52 | — | — | Form 4 |
| Griffith Hugh | director, officer: Chief Executive Officer | Mar 18, 2026 | OTHER | 831,561,761 | — | — | Form 4 |